Xiaohong Wu1, Feiqing Zhou2, Xiuhai Ji3, Kewei Ren4, Ye Shan5, Xuhua Mao6, Yan Fen7, Ruhua Chen7, Hui Ding7, Xingli Fu8. 1. Department of Gastrointestinal Surgery, Yixing People Hospital, Affiliated Jiangsu University, 214200, China. 2. Department of Medical Examination Center, The Affiliated Yixing Hospital of Jiangsu University, Yixing, Jiangsu, 214200, China. 3. Department of Oncology, Affiliated Taicang Hospital of Traditional Chinese Medicine, Suzhou, 215400, China. 4. Department of Orthopedics, The Affiliated Jiangyin Hospital of Southeast University Medical School, Jiangyin, 214400, China. 5. Department of Critical Care Medicine, The Affiliated Yixing Hospital of Jiangsu University, Yixing, Jiangsu, 214200, China. 6. Department of Clinical Laboratory, Yixing People Hospital, Affiliated Jiangsu University, 214200, China. 7. Department of Respiratory Medicine, Yixing People Hospital, Affiliated Jiangsu University, 214200, China. 8. Jiangsu University Health Science Center, Yizheng Road, Zhenjiang, Jiangsu, 212001, China.
Abstract
AIM: We aimed to investigate a practical profile of MAC30 on chemotherapeutic response in gastric cancer (GC). PATIENTS & METHODS: We elected 87 GC patients receiving platinum-based chemotherapy in this study. MAC30 levels in tumor and adjuvant nontumor tissues were confirmed via reverse transcription-PCR to identify the clinical profile in GC and the correlation with therapeutic response. RESULTS: We found elevated MAC30 in GC compared with the matched adjacent nontumor tissues. GC with enhanced MAC30 exhibited poorer survival by Kaplan-Meier analysis and poor response to adjuvant platinum-based chemotherapy. A multivariate analysis showed that MAC30 was an independent prognostic factor of overall survival in GC receiving platinum-based chemotherapy. CONCLUSION: MAC30 could play as a potential biomarker for prognosis of GC with platinum-based chemotherapy.
AIM: We aimed to investigate a practical profile of MAC30 on chemotherapeutic response in gastric cancer (GC). PATIENTS & METHODS: We elected 87 GC patients receiving platinum-based chemotherapy in this study. MAC30 levels in tumor and adjuvant nontumor tissues were confirmed via reverse transcription-PCR to identify the clinical profile in GC and the correlation with therapeutic response. RESULTS: We found elevated MAC30 in GC compared with the matched adjacent nontumor tissues. GC with enhanced MAC30 exhibited poorer survival by Kaplan-Meier analysis and poor response to adjuvant platinum-based chemotherapy. A multivariate analysis showed that MAC30 was an independent prognostic factor of overall survival in GC receiving platinum-based chemotherapy. CONCLUSION:MAC30 could play as a potential biomarker for prognosis of GC with platinum-based chemotherapy.